94.15

2.56% -2.47

Blueprint Medicines Corp (BPMC)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BPMC Giù? Forum Previsione

Precedente Chiudi:

$96.62

Aprire:

$96.78

Volume 24 ore:

653.05K

Relative Volume:

1.07

Capitalizzazione di mercato:

$5.90B

Reddito:

$434.41M

Utile/perdita netta:

$-128.05M

Rapporto P/E:

-10.24

EPS:

-9.19

Flusso di cassa netto:

$-250.52M

1 W Prestazione:

+6.16%

1M Prestazione:

+8.88%

6M Prestazione:

-8.33%

1 anno Prestazione:

+40.50%

Intervallo 1D:

$94.11

$98.34

Intervallo di 1 settimana:

$88.05

$98.34

Portata 52W:

$66.61

$121.90

Blueprint Medicines Corp Stock (BPMC) Company Profile

Nome

Blueprint Medicines Corp

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

617-374-7580

Indirizzo

45 SIDNEY STREET, CAMBRIDGE, MA

Dipendente

655

Cinguettio

@BlueprintMeds

Prossima data di guadagno

2024-10-30

Ultimi documenti SEC

BPMC's Discussions on Twitter

Confronta BPMC con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BPMC	94.15	5.90B	434.41M	-128.05M	-250.52M	-9.19
VRTX	450.97	116.38B	10.63B	-479.80M	-1.35B	13.33
REGN	738.00	82.09B	13.85B	4.65B	3.32B	35.06
ARGX	605.92	36.14B	1.86B	-40.29M	-1.28B	-4.16
ALNY	244.89	31.59B	2.09B	-332.26M	16.06M	-4.14
BNTX	113.13	27.25B	3.30B	-501.07M	1.03B	11.54

Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-10-27	Aggiornamento	Oppenheimer	Perform → Outperform
2023-08-21	Reiterato	Needham	Buy
2023-07-31	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-06-05	Downgrade	SVB Securities	Market Perform → Underperform
2023-01-03	Aggiornamento	Wells Fargo	Underweight → Equal Weight
2022-12-14	Iniziato	Needham	Buy
2022-11-02	Downgrade	Oppenheimer	Outperform → Perform
2022-09-14	Iniziato	Berenberg	Buy
2022-07-08	Iniziato	Oppenheimer	Outperform
2022-06-27	Iniziato	Wells Fargo	Underweight
2022-06-10	Downgrade	Citigroup	Neutral → Sell
2022-06-01	Aggiornamento	Jefferies	Hold → Buy
2022-03-01	Iniziato	Citigroup	Neutral
2022-02-17	Downgrade	SVB Leerink	Outperform → Mkt Perform
2022-01-25	Aggiornamento	Stifel	Hold → Buy
2021-11-19	Ripresa	Morgan Stanley	Equal-Weight
2021-09-30	Ripresa	Stifel	Hold
2021-06-04	Ripresa	Robert W. Baird	Outperform
2021-03-31	Iniziato	Credit Suisse	Neutral
2020-12-03	Iniziato	Stifel	Hold
2020-11-02	Reiterato	H.C. Wainwright	Buy
2020-11-02	Downgrade	Jefferies	Buy → Hold
2020-10-30	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2020-07-15	Reiterato	H.C. Wainwright	Buy
2020-05-05	Iniziato	Barclays	Equal Weight
2020-03-17	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2020-01-28	Iniziato	BMO Capital Markets	Market Perform
2020-01-27	Iniziato	BMO Capital Markets	Market Perform
2019-11-06	Aggiornamento	Raymond James	Outperform → Strong Buy
2019-10-22	Iniziato	JMP Securities	Mkt Outperform
2019-10-03	Iniziato	H.C. Wainwright	Buy
2019-09-12	Aggiornamento	Raymond James	Mkt Perform → Outperform
2019-08-29	Iniziato	Piper Jaffray	Neutral
2019-08-15	Ripresa	Raymond James	Mkt Perform
2019-07-18	Iniziato	Deutsche Bank	Buy
2019-05-23	Ripresa	Goldman	Buy
2019-04-03	Iniziato	Morgan Stanley	Overweight
2018-09-25	Iniziato	Leerink Partners	Outperform
2017-12-11	Reiterato	Goldman	Buy

Mostra tutto

Blueprint Medicines Corp Borsa (BPMC) Ultime notizie

Nov 22, 2024

Blueprint Medicines director Coats sells $1.87 million in stock - Investing.com

Nov 22, 2024

Nov 21, 2024

What is Zacks Research's Forecast for BPMC FY2024 Earnings? - MarketBeat

Nov 21, 2024

Segall Bryant & Hamill LLC Buys 14,668 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Nov 21, 2024

Nov 20, 2024

Blueprint Medicines (LTS:0HOJ) Enterprise Value : $5,746.9 Mil (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024

Blueprint Medicines initiated with an Overweight at JPMorgan - MSN

Nov 20, 2024

Blueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Cut by Victory Capital Management Inc. - MarketBeat

Nov 20, 2024

Nov 18, 2024

JMP Securities Reaffirms Market Outperform Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat

Nov 18, 2024

Blueprint Medicines’ (BPMC) “Buy” Rating Reiterated at Needham & Company LLC - Defense World

Nov 18, 2024

Blueprint Medicines’ (BPMC) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 18, 2024

Nov 17, 2024

Prime Capital Investment Advisors LLC Sells 6,476 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Nov 17, 2024

Nov 16, 2024

Blueprint Medicines Co. (NASDAQ:BPMC) Sees Large Growth in Short Interest - MarketBeat

Nov 16, 2024

Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 16, 2024

Nov 15, 2024

Blueprint Medicines (NASDAQ:BPMC) Given Buy Rating at Needham & Company LLC - MarketBeat

Nov 15, 2024

HC Wainwright Reiterates Buy Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat

Nov 15, 2024

JP Morgan Initiates Coverage of Blueprint Medicines (BPMC) with Overweight Recommendation - MSN

Nov 15, 2024

Nov 14, 2024

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst - Yahoo Finance

Nov 14, 2024

Key Takeaways From Blueprint Medicines Analyst Ratings - Benzinga

Nov 14, 2024

Blueprint Medicines (NASDAQ:BPMC) Now Covered by JPMorgan Chase & Co. - MarketBeat

Nov 14, 2024

Mastocytosis Treatment Market Forecasted for Major Expansion - openPR

Nov 14, 2024

Entropy Technologies LP Takes Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Nov 14, 2024

Nov 09, 2024

Blueprint Medicines Co. (NASDAQ:BPMC) Holdings Raised by US Bancorp DE - MarketBeat

Nov 09, 2024

Nov 08, 2024

M&G Plc Makes New $9.10 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Nov 08, 2024

Blueprint Medicines (NASDAQ:BPMC) Stock Rating Upgraded by StockNews.com - MarketBeat

Nov 08, 2024

Nov 05, 2024

Blueprint Medicines' SWOT analysis: stock soars on Ayvakit success, pipeline potential - Investing.com

Nov 05, 2024

Blueprint Medicines discloses CDK2 inhibitors for cancer - BioWorld Online

Nov 05, 2024

Nov 04, 2024

Systemic Mastocytosis Treatment Market to Grow by USD 157.1 Million from 2024-2028, Driven by Aging Population and AI-Redefined Market LandscapeTechnavio - The Malaysian Reserve

Nov 04, 2024

Blueprint Medicines (NASDAQ:BPMC) Price Target Lowered to $151.00 at Wells Fargo & Company - Defense World

Nov 04, 2024

Q1 Earnings Forecast for BPMC Issued By HC Wainwright - MarketBeat

Nov 04, 2024

Nov 03, 2024

Emerald Advisers LLC Has $34.77 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Nov 03, 2024

Blueprint Medicines (NASDAQ:BPMC) Given “Buy” Rating at Needham & Company LLC - Defense World

Nov 03, 2024

Nov 02, 2024

Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report - Yahoo Finance

Nov 02, 2024

Nov 01, 2024

Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance

Nov 01, 2024

Q4 EPS Estimates for Blueprint Medicines Boosted by Wedbush - MarketBeat

Nov 01, 2024

Oct 31, 2024

Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales By Investing.com - Investing.com South Africa

Oct 31, 2024

Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales - Investing.com

Oct 31, 2024

Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2024 Earnings Call Transcript - Insider Monkey

Oct 31, 2024

Blueprint Medicines stock target upgraded, buy rating on Ayvakit sales - Investing.com

Oct 31, 2024

Blueprint Medicines (NASDAQ:BPMC) Receives "Buy" Rating from HC Wainwright - MarketBeat

Oct 31, 2024